Haematologica · 2017 · 46 citations · 37 references
MedicineGeneticsOncologyCytogeneticsGenomicsMolecular OncologyCancer CytogeneticsCancer GenomicsCancer Molecular DiagnosticsMinimal Residual DiseaseMolecular CytogeneticsMutation AnalysisAcute LeukemiasChromosomal Copy Number AberrationsCytogenetic Prognostic MarkersDna In Situ HybridizationLeukemia CytogeneticsMinimal Residual Disease MarkersRelapsed LeukemiaStructural Chromosomal Aberrations
The genetic landscape of adult acute myeloid leukemias (AML) has been recently unraveled. However, due to their genetic heterogeneity, only a handful of markers are currently used for the evaluation of minimal residual disease (MRD). Recent studies using multi-target strategies indicate that detection of residual mutations in less than 5% of cells in complete remission is associated with a better survival. Here, in a series of 69 AMLs with known clonal architecture, we design a clone-specific strategy based on fluorescent in situ hybridization and high-sensitivity next generation sequencing to detect chromosomal aberrations and mutations, respectively, in follow-up samples. The combination of these techniques allows tracking chromosomal and genomic lesions down to 0.5–0.4% of the cell population in remission samples. By testing all lesions in follow-up samples from 65 of 69 evaluable patients, we find that initiating events often persist and appear to be, on their own, inappropriate markers to predict short-term relapse. In contrast, the persistence of two or more lesions in more than 0.4% of the cells from remission samples is strongly associated with lower leukemia-free and overall survivals in univariate and multivariate analyses. Although larger prospective studies are needed to extend these results, our data show that a personalized, clone-specific, MRD follow up strategy is feasible in the vast majority of AML cases.
37
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Siddhartha Jaiswal, Pierre Fontanillas, Jason Flannick et al. · New England Journal of Medicine · 2014 · 4.7K citations · Full text
Life Sciences, Genetics, Hematology +17
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil, Moritz Gerstung, Lars Bullinger et al. · New England Journal of Medicine · 2016 · 4.4K citations · Full text
Life Sciences, Genetics, Oncology +14
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
David P. Steensma, Rafael Bejar, Siddhartha Jaiswal et al. · Blood · 2015 · 1.9K citations · Full text
Medicine, Hematology, Pathology +16